Travere Therapeutics to Present at Guggenheim Biotech Summit 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy TVTX?
Source: Newsfilter
- Event Announcement: Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 4:00 p.m. ET, showcasing the company's latest advancements in the rare disease sector.
- Live Webcast: The presentation will be accessible via a live webcast on Travere's investor page at ir.travere.com/events-and-presentations, with a replay available for 30 days post-event, ensuring that investors unable to attend live can still access the information.
- Company Mission: Travere Therapeutics focuses on providing urgently needed treatment options for patients with rare diseases and their families, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, reflecting the company's commitment to patient needs.
- Future Outlook: By participating in this summit, Travere aims to enhance its influence in the biopharmaceutical industry, demonstrating its innovative efforts in rare disease treatment and boosting investor confidence in the company's future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 42.89 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 29.470
Low
31.00
Averages
42.89
High
49.00
Current: 29.470
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Travere Therapeutics to Present at Guggenheim Biotech Summit 2026
- Event Announcement: Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 4:00 p.m. ET, showcasing the company's latest advancements in the rare disease sector.
- Live Webcast: The presentation will be accessible via a live webcast on Travere's investor page at ir.travere.com/events-and-presentations, with a replay available for 30 days post-event, ensuring that investors unable to attend live can still access the information.
- Company Mission: Travere Therapeutics focuses on providing urgently needed treatment options for patients with rare diseases and their families, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, reflecting the company's commitment to patient needs.
- Future Outlook: By participating in this summit, Travere aims to enhance its influence in the biopharmaceutical industry, demonstrating its innovative efforts in rare disease treatment and boosting investor confidence in the company's future growth.
See More
Investigation into Potential Securities Violations at Travere Therapeutics
- Investigation Background: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics, Inc., focusing on whether the company and its executives made materially false or misleading statements or omitted critical information that could harm investors.
- Investor Call to Action: The firm is urging any Travere investors with relevant information, particularly those who have suffered losses, to come forward to assist in the investigation and pursue potential compensation for their losses.
- Company Overview: Travere Therapeutics is a biopharmaceutical company dedicated to developing therapies for rare kidney and metabolic diseases, primarily serving the U.S. market, highlighting its specialization and the demand in this niche medical field.
- Law Firm's Strength: Robbins Geller is one of the world's leading law firms in securities fraud and shareholder litigation, having been ranked #1 in ISS Securities Class Action Services for four out of the last five years, recovering over $2.5 billion for investors in 2024 alone, underscoring its significant influence in the industry.
See More
Robbins Geller Investigates Potential Securities Violations by Travere Therapeutics
- Investigation Launched: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics (NASDAQ: TVTX), focusing on whether executives made materially false or misleading statements that could undermine investor confidence.
- Investor Loss Focus: The investigation particularly targets investors who suffered losses in Travere, with the firm encouraging affected individuals to provide information, demonstrating a commitment to protecting investor rights.
- Law Firm Strength: Robbins Geller is recognized as one of the world's leading law firms in securities fraud and shareholder litigation, having ranked #1 in ISS Securities Class Action Services for four out of the last five years, highlighting its strong capability in securing investor compensation.
- Historical Recovery Record: In 2024, the firm recovered over $2.5 billion for investors in securities-related class action cases, surpassing the combined total of the next five law firms, showcasing its exceptional performance in the securities litigation arena.
See More
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Market Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing robust market demand for its products.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, driving total revenue up from $62.9 million to $164.9 million, highlighting its strong performance in the rare disease treatment sector.
- FDA Review Catalyst: The ongoing FDA review of Travere's FILSPARI for potential use in treating focal segmental glomerulosclerosis has heightened market expectations for the company, further bolstering Palisades' investment confidence.
See More
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Stock Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing market recognition of its potential value.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, contributing to a total revenue increase from $62.9 million to $164.9 million, demonstrating strong market demand for its products.
- FDA Review Catalyst: With the FDA reviewing Travere's FILSPARI for potential approval in specific disease treatments, Palisades' investment reflects optimism about Travere's future market performance, especially with anticipated growth following potential FDA approval.
See More
Palisades Acquires 137,768 Shares of Travere Therapeutics for $5.26 Million
- New Investment Position: Palisades Investment Partners initiated a new position by acquiring 137,768 shares of Travere Therapeutics in Q4 2025 for an estimated $5.26 million, indicating a bullish outlook as the stock was on the rise.
- Asset Allocation Impact: This acquisition represents 1.99% of Palisades' 13F assets, highlighting Travere's significance within the firm's total reportable U.S. equity assets of $264.72 million.
- Revenue Growth Highlight: Travere Therapeutics reported a remarkable 155% year-over-year increase in FILSPARI sales to $90.9 million in Q3, contributing to a total revenue surge from $62.9 million last year to $164.9 million, reflecting strong market demand.
- FDA Review Influence: The stock price of Travere surged in Q4 2025, reaching a peak of $42.13, driven by news of the FDA reviewing FILSPARI for potential approval, suggesting optimistic market expectations for future growth.
See More
Travere Therapeutics to Present at Guggenheim Biotech Summit 2026
- Event Announcement: Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 4:00 p.m. ET, showcasing the company's latest advancements in the rare disease sector.
- Live Webcast: The presentation will be accessible via a live webcast on Travere's investor page at ir.travere.com/events-and-presentations, with a replay available for 30 days post-event, ensuring that investors unable to attend live can still access the information.
- Company Mission: Travere Therapeutics focuses on providing urgently needed treatment options for patients with rare diseases and their families, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, reflecting the company's commitment to patient needs.
- Future Outlook: By participating in this summit, Travere aims to enhance its influence in the biopharmaceutical industry, demonstrating its innovative efforts in rare disease treatment and boosting investor confidence in the company's future growth.
See More
Investigation into Potential Securities Violations at Travere Therapeutics
- Investigation Background: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics, Inc., focusing on whether the company and its executives made materially false or misleading statements or omitted critical information that could harm investors.
- Investor Call to Action: The firm is urging any Travere investors with relevant information, particularly those who have suffered losses, to come forward to assist in the investigation and pursue potential compensation for their losses.
- Company Overview: Travere Therapeutics is a biopharmaceutical company dedicated to developing therapies for rare kidney and metabolic diseases, primarily serving the U.S. market, highlighting its specialization and the demand in this niche medical field.
- Law Firm's Strength: Robbins Geller is one of the world's leading law firms in securities fraud and shareholder litigation, having been ranked #1 in ISS Securities Class Action Services for four out of the last five years, recovering over $2.5 billion for investors in 2024 alone, underscoring its significant influence in the industry.
See More
Robbins Geller Investigates Potential Securities Violations by Travere Therapeutics
- Investigation Launched: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics (NASDAQ: TVTX), focusing on whether executives made materially false or misleading statements that could undermine investor confidence.
- Investor Loss Focus: The investigation particularly targets investors who suffered losses in Travere, with the firm encouraging affected individuals to provide information, demonstrating a commitment to protecting investor rights.
- Law Firm Strength: Robbins Geller is recognized as one of the world's leading law firms in securities fraud and shareholder litigation, having ranked #1 in ISS Securities Class Action Services for four out of the last five years, highlighting its strong capability in securing investor compensation.
- Historical Recovery Record: In 2024, the firm recovered over $2.5 billion for investors in securities-related class action cases, surpassing the combined total of the next five law firms, showcasing its exceptional performance in the securities litigation arena.
See More
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Market Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing robust market demand for its products.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, driving total revenue up from $62.9 million to $164.9 million, highlighting its strong performance in the rare disease treatment sector.
- FDA Review Catalyst: The ongoing FDA review of Travere's FILSPARI for potential use in treating focal segmental glomerulosclerosis has heightened market expectations for the company, further bolstering Palisades' investment confidence.
See More
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Stock Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing market recognition of its potential value.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, contributing to a total revenue increase from $62.9 million to $164.9 million, demonstrating strong market demand for its products.
- FDA Review Catalyst: With the FDA reviewing Travere's FILSPARI for potential approval in specific disease treatments, Palisades' investment reflects optimism about Travere's future market performance, especially with anticipated growth following potential FDA approval.
See More
Palisades Acquires 137,768 Shares of Travere Therapeutics for $5.26 Million
- New Investment Position: Palisades Investment Partners initiated a new position by acquiring 137,768 shares of Travere Therapeutics in Q4 2025 for an estimated $5.26 million, indicating a bullish outlook as the stock was on the rise.
- Asset Allocation Impact: This acquisition represents 1.99% of Palisades' 13F assets, highlighting Travere's significance within the firm's total reportable U.S. equity assets of $264.72 million.
- Revenue Growth Highlight: Travere Therapeutics reported a remarkable 155% year-over-year increase in FILSPARI sales to $90.9 million in Q3, contributing to a total revenue surge from $62.9 million last year to $164.9 million, reflecting strong market demand.
- FDA Review Influence: The stock price of Travere surged in Q4 2025, reaching a peak of $42.13, driven by news of the FDA reviewing FILSPARI for potential approval, suggesting optimistic market expectations for future growth.
See More
